Education
About Us
Working with TipRanks
Follow Us
Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Total Valuation
Lincoln Pharmaceuticals Ltd has a market cap or net worth of ₹11.56B. The enterprise value is ₹6.76B.
Market Cap₹11.56B
Enterprise Value₹6.76B
Share Statistics
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,029,728
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lincoln Pharmaceuticals Ltd’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 9.67%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)9.67%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.78
Inventory Turnover3.70
Valuation Ratios
The current PE Ratio of Lincoln Pharmaceuticals Ltd is 13.43. Lincoln Pharmaceuticals Ltd’s PEG ratio is 0.79.
PE Ratio13.43
PS Ratio0.00
PB Ratio1.44
Price to Fair Value1.65
Price to FCF20.33
Price to Operating Cash Flow8.17
PEG Ratio0.79
Income Statement
In the last 12 months, Lincoln Pharmaceuticals Ltd had revenue of 6.23B and earned 823.46M in profits. Earnings per share was 41.11.
Revenue6.23B
Gross Profit3.32B
Operating Income885.94M
Pretax Income1.09B
Net Income823.46M
EBITDA1.24B
Earnings Per Share (EPS)41.11
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Lincoln Pharmaceuticals Ltd pays an annual dividend of ₹1.799, resulting in a dividend yield of 0.31%
Dividend Per Share₹1.799
Dividend Yield0.31%
Payout Ratio4.38%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-5.95%
50-Day Moving Average570.61
200-Day Moving Average664.14
Relative Strength Index (RSI)49.33
Average Volume (3m)6.38K
Important Dates
Lincoln Pharmaceuticals Ltd upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 22, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend DateSep 13, 2024
Financial Position
Lincoln Pharmaceuticals Ltd as a current ratio of 4.71, with Debt / Equity ratio of 0.47%
Current Ratio4.71
Quick Ratio3.97
Debt to Market Cap0.00
Net Debt to EBITDA-0.11
Interest Coverage Ratio47.05
Taxes
In the past 12 months, Lincoln Pharmaceuticals Ltd has paid 268.42M in taxes.
Income Tax268.42M
Effective Tax Rate0.25
Enterprise Valuation
Lincoln Pharmaceuticals Ltd EV to EBITDA ratio is 8.81, with an EV/FCF ratio of 14.81.
EV to Sales1.75
EV to EBITDA8.81
EV to Free Cash Flow14.81
EV to Operating Cash Flow11.75
Balance Sheet
Lincoln Pharmaceuticals Ltd has ₹1.97B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹1.97B billion.
Cash & Marketable Securities₹1.97B
Total Debt₹0.00
Net Cash-₹1.97B
Net Cash Per Share-₹98.52
Tangible Book Value Per Share₹335.10
Margins
Gross margin is 53.06%, with operating margin of 14.22%, and net profit margin of 13.21%.
Gross Margin53.06%
Operating Margin14.22%
Pretax Margin17.52%
Net Profit Margin13.21%
EBITDA Margin19.89%
EBIT Margin17.82%
Analyst Forecast
The average price target for Lincoln Pharmaceuticals Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―